Early Diagnosis of Brain Metastases Using a Biofluids-Metabolomics Approach in Mice
Open Access
- 1 January 2016
- journal article
- Published by Ivyspring International Publisher in Theranostics
- Vol. 6 (12) , 2161-2169
Abstract
Over 20% of cancer patients will develop brain metastases. Prognosis is currently extremely poor, largely owing to late-stage diagnosis. We hypothesized that biofluid metabolomics could detect tumours at the micrometastatic stage, prior to the current clinical gold-standard of blood-brain barrier breakdown.Keywords
This publication has 27 references indexed in Scilit:
- A type 2 biomarker separates relapsing-remitting from secondary progressive multiple sclerosisNeurology, 2014
- The role of magnetic resonance imaging in the management of brain metastases: diagnosis to prognosisCancer Imaging, 2014
- A robust automatic phase correction method for signal dense spectraJournal of Magnetic Resonance, 2013
- Structural and functional effects of metastases in rat brain determined by multimodal MRIInternational Journal of Cancer, 2013
- Urinary metabolomic signature of esophageal cancer and Barrett’s esophagusWorld Journal of Surgical Oncology, 2012
- Epidemiology of Brain MetastasesCurrent Oncology Reports, 2011
- A New Prognostic Index and Comparison to Three Other Indices for Patients With Brain Metastases: An Analysis of 1,960 Patients in the RTOG DatabaseInternational Journal of Radiation Oncology - Biology - Physics (IJROBP), 2008
- Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extractsNature Protocols, 2007
- Magnetic resonance imaging and computed tomography in the diagnoses of brain metastases of lung cancerLung Cancer, 2004
- Study of cytokine induced neuropathology by high resolution proton NMR spectroscopy of rat urineFEBS Letters, 2004